Minnesota Study Links Medical Cannabis to Reduced Anxiety in Autism Patients

Minnesota's Cannabis Management Office released a comprehensive report analyzing data from 1,811 patients with autism spectrum disorder using medical cannabis, documenting reported improvements in anxiety symptoms. The study represents one of the largest real-world assessments of cannabinoid therapy in autistic populations, providing valuable insights into potential therapeutic applications. Participants reported notable reductions in anxiety-related behaviors, a common co-occurring condition affecting quality of life in autism. However, researchers emphasized important methodological considerations and the need for controlled clinical trials to establish efficacy and optimal dosing protocols. This research contributes to growing evidence supporting further investigation into medical cannabis as a complementary treatment option for autism-related anxiety.